New data on lecanemab to be presented at the 14[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference
Stockholm, November 4, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai today announced that they will hold several oral presentations revealing new data on lecanemab, at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 9-12, 2021, in Boston, Massachusetts and virtually. The presentations will provide deeper insights into lecanemab’s potential as a treatment for early Alzheimer’s disease.Eisai recently initiated a rolling submission of a Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril